tbuckley/cabot-search huggingface dataset:
Metronomic oral cyclophosphamide (CTX) in patients (pts) with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC)
Authors: E. Fea, P. Vanella, E. Miraglio, C. Cauchi, I. Colantonio, N. Denaro, G. Di Costanzo, O. Garrone, C. Granetto, M. Occelli, V. Ricci, A.M. Vandone, M.C. Merlano
Journal: Annals of Oncology (2016)
CBIO-20. METABOLIC VULNERABILITY REVEALED IN SLOW-CYCLING GLIOMA STEM CELLS
Authors: Lan Hoang-Minh, Michael Schmoll, Krisha Amin, Kyle Dajac, Alvin Vuong, Jianping Huang, Changlin Yang, Timothy Garrett, Matthew Sarkisian, Brent Reynolds, Loic Deleyrolle
Journal: Neuro-Oncology (2016)

Current cancer therapeutics effectively eliminate rapidly proliferating cells but spare slowly dividing populations. Expansion of these therapy-selected slow-cycling cells might therefore contribute to a significant portion of relapses. We previously reported the existence of slow-cycling cells that exhibit cancer stem cell characteristics and resistance to therapies in glioblastoma (GBM). Eradicating this specific phenotype appears to be an important objective in cancer therapy. Actively proliferative cells are typically marked by aerobic glycolysis. In contrast, slow-dividing cells appear to rely on oxidative phosphorylation (OxPhos) to meet energy demands. Exploiting the altered metabolism of cancer cells for treatment has become a generally accepted concept. The demonstration of slow-cycling glioma-cell reliance on OxPhos may reveal a targetable vulnerability, which could be used to eradicate this treatment-resistant population. Our objective is to characterize the energetic properties of glioma stem cells (especially slow-cycling cells) and demonstrate their sensitivity to mitochondrial targeting. Slow and fast-cycling cells were isolated from patient-derived primary GBMs, and separated by flow cytometry based on their ability to retain the dye carboxy-fluorescein-succinimidyl-ester. These two isolated populations were compared with respect to metabolic profile and sensitivity to multiple metabolic therapies. Metabolomics studies confirmed metabolic heterogeneity in GBM with differential metabolic signatures between fast and slow-cycling cells. Fast-cycling cells showed a glycolytic phenotype, whereas slow-cycling cells demonstrated an OxPhos profile. Although the slow-cycling fraction was less sensitive to glycolysis inhibition, it demonstrated particular sensitivity to OxPhos blockade. The dual inhibition of glycolysis and mitochondrial respiration provided therapeutic benefits by targeting metabolically distinct populations and preventing metabolic adaptation. These findings indicate the existence of metabolic heterogeneity in GBM, and suggest that subpopulations of treatment-resistant cells, which contribute to relapse, may rely on OxPhos rather than aerobic glycolysis, revealing susceptibilities that could be exploited therapeutically.
In Vitro Growth of Lucké Tumor Cells
Authors: Allan Granoff
Journal: JNCI Journal of the National Cancer Institute (1973)

Journal Article In Vitro Growth of Lucké Tumor Cells Get access Allan Granoff, Ph.D. Allan Granoff, Ph.D. Laboratories of Virology and Immunology, St. Jude Children's Research Hospital, Memphis, Tennessee 38101 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 51, Issue 3, September 1973, Page 1087, https://doi.org/10.1093/jnci/51.3.1087 Published: 01 September 1973
Phase II study of idelalisib, a selective inhibitor of PI3Kδ, for relapsed/refractory classical Hodgkin lymphoma
Authors: A.K. Gopal, M.A. Fanale, C.H. Moskowitz, A.R. Shustov, S. Mitra, W. Ye, A. Younes, A.J. Moskowitz
Journal: Annals of Oncology (2017)
Pathologic response and survival after cisplatin, pemetrexed, and bevacizumab followed by surgery for clinical stage II/IIIA non-squamous non-small cell lung cancer
Authors: Y. Tsutani, Y. Miyata, K. Suzuki, K. Takamochi, F. Tanaka, H. Nakayama, Y. Yamashita, M. Oda, M. Tsuboi, M. Okada
Journal: Annals of Oncology (2016)
Selective Splenic Artery Embolization for the Treatment of Thrombocytopenia and Hypersplenism in Paroxysmal Nocturnal Hemoglobinuria (PNH)
Authors: Anna Paola Iori, Karen Brown, David J. Araten, Emilia Scalzulli, Giovanni Fernando Torelli, Maria Stefania De Propris, Corrado Girmenia, Filippo Maria Salvatori, Orly Zelig, Robin Foa, Lucio Luzzatto
Journal: Blood (2012)
CBIO-01. THE EARLY CHANGES IN PROTEIN EXPRESSION IN THE RHESUS OPTIC NERVES INJURED BY A SINGLE DOSE/FRACTIONATION STEREOTACTIC RADIOSURGERY
Authors: Jing Chen, ShuangMin Fan
Journal: Neuro-Oncology (2016)

Radiation-induced optic neuropathy (RION) is a severe complication when we use stereotactic radiosurgery (SRS) to treat anterior visual disease. This study was designed to analyze the early changes in protein expression in rhesus optic nerves injured by SRS. The left side intraorbital optic nerves of 3 rhesus monkeys (6-8 years)were injured by gamma knife surgery (GKS) (marginal dose of 15 Gy, 50% isodose curve), while the contralateral optic nerves served as the control. The bilateral intraorbital optic nerves of 3 rhesus monkeys were dissected and performed a non-marker quantitative proteomic analysis at 72 hours after GKS. The differential expression protein information was obtained. The functional information of those proteins was obtained through the BLAST sequence alignment with the human proteomic. The result showed that 41 proteins fit the criteria for differential expression (change>2.0-fold, P value<0.05 or exclusive expression). 7 proteins were significantly down-regulated (change>2.0-fold, P value<0.05) at the injured optic nerves. 18 proteins were exclusively expressed in the contralateral optic nerves. And 16 proteins were exclusively expressed in the injured optic nerves. In general, this study indicated that the single dose of 15 Gy on a 50% isodose curve in the optic nerve had a significant impact on protein expression at 72 hours after GKS. Non-marker quantitative analysis based on high-resolution LCMS/MS can be used to detect the early protein expression change in RION. At 72h after GKS, The cell’s endocytosis and pinocytosis were declined and shown a significant inflammation and immunization. The proliferation of those cell were declined and the genetic transcription and translation were increased in the injury optic.
Prognostic value of hpv infection by e1 detection and p16 expression in 78 oropharyngeal squamous cell carcinomas
Authors: C. Lo Nigro, D. Vivenza, L. Lattanzio, M. Fortunato, N. Denaro, C. Varamo, M. Ferrero, E. Russi, M. Merlano
Journal: Annals of Oncology (2016)
Retrospective analysis of the efficacy of somatostatin analogs (SSA) in metastatic pulmonary neuroendocrine tumors and prognostic significance of FDG-PET
Authors: A. Bongiovanni, F. Recine, G. Marcantognini, N. Riva, V. Fausti, C. Liverani, A. de vita, L. Mercatali, F. Foca, M. Sansovini, F. Pieri, D. Oboldi, R. Galassi, D. Cavaliere, A. Zaccaroni, A. Tartaglia, V. Lunedei, A. Gardini, D. Amadori, T. Ibrahim
Journal: Annals of Oncology (2016)
Efficacy of cabozantinib (cabo) vs everolimus (eve) by metastatic site and tumor burden in patients (pts) with advanced renal cell carcinoma (RCC) in the phase 3 METEOR trial
Authors: T.B. Powles, B. Escudier, P. de Souza, S. Chowdhury, D. Pook, U. Harmenberg, N. Basappa, D. Geynisman, J. Merchan, B.G. Redman, C. Ryan, O. Goodman, T. Ho, P. Singh, J. Lougheed, M. Patel, J.J. Knox, R.J. Motzer, T.K. Choueiri
Journal: Annals of Oncology (2016)
Dexamethasone (Dex) Inhibits Anti-GPIIIa49-66 Ab Induced Oxidative Fragmenation of Platelets: Inhibition of Platelet Phospholipase A2 (PLA2) and 12-Lipoxygenase (12-LO) MembraneTranslocation and Activity.
Authors: Michael A. Nardi, Steven J. Feinmark, Yelena Gor, Simon Karpatkin
Journal: Blood (2006)
Clinical and pathological features of rare histological exocrine pancreatic cancers (PCs): a retrospective multicentric analysis
Authors: N. Silvestris, O. Brunetti, P. Marchetti, F. Mazzuca, E. Vasile, F. Gelsomino, S. Zanon, A. Giardini Casadei, M. Milella, D. Basile, S. Barni, M. Scartozzi, A. Laffi, S. Delfanti, C. Cella, F. De Vita, G. Giusi, V. Lorusso, A. Scarpa, S. Cascinu
Journal: Annals of Oncology (2016)
CSIG-03. SMALL RNA SEQUENCING OF GLIOBLASTOMA MULTIFORME EXTRACELLULAR VESICLES
Authors: Tristan de Mooij, Brandon McCutcheon
Journal: Neuro-Oncology (2016)

Glioblastoma (GBM) subverts the immune system towards immunosuppression through transfer of oncogenic components, including non-coding RNAs, via extracellular vesicles (EVs). GBM-derived EVs are detectable in blood and CSF and may one-day serve as liquid biopsies. EVs of 5 adult GBM cell lines generated at our institution from primary GBMs were harvested after serum-free culture and purified via sequential centrifugation. RNA was collected using the miRNAeasy kit (Qiagen) and sequenced with Illumina HiSeq 2000. Data was analyzed using the OASIS-2.0 platform using HG38. MirTarBase and MirDB interrogated validated and predicted microRNA-gene interactions. 712 of 28623 interrogated non-coding mi/pi/sno/sn/r-RNAs were expressed, most of which novel associations with GBM EVs. Hsa-miR-21-5p, hsa-let-7b-5p, hsa-miR-3182, hsa-miR-4448, hsa-let-7i-5p were most expressed; miRNAs and piRNAs combined generated 92-98% total expression. 10 miRNAs and 13 piRNAs constituted >50% total expression per RNA species per sample. The miRNA gene targeting profile was highly conserved and focused on PTEN, BCL2 and IGF1R, culminating in the silencing of cell cycle, PI3K/Akt, MAPK, p53 and Glioma KEGG pathways. MirDeep2 predicted 4 robustly expressed novel microRNAs with mature sequences aguggggccacgagcugaga, uagugguuaguacccugccuug, acagauugagagcucuuuu and auuucuguccaacuucug. Predicted gene targets of novel miRNAs closely overlapped those of validated miRNAs. Hierarchical clustering demonstrated dBT165 and dBT114 as a separate group based on total/mi/pi/r-RNA, and was predictive of >2 years survival. Hsa-miR-5585-3p (p-value: 0.04, fold-change: 2.8), hsa_piR_020365 (p-value:0.016, fold-change: 7, 17th highest overall expression), hsa_piR_008624 (p-value:0.017, fold-change: 3.6), as well as total hsa-mir-34 family expression (p-value: 0.018), total piRNA (p-value: 0.047) and snRNA (p-value: 0.035) expression were predictive of <2 years survival. We demonstrated expression of previously unassociated RNAs, including 4 novel miRNAs, and detailed clinical and prognostic relevance. Identification of non-coding RNAs and gene/pathway silencing analyses are of paramount importance for development of diagnostic and prognostic tools, providing pathophysiologic understanding, and, in the future, potentially direct decision-making.
CBIO-16. TRANS-ENDOTHELIAL MIGRATION OF NON-SMALL CELL LUNG CANCER CELLS THROUGH THE BLOOD BRAIN BARRIER: ROLE OF CD15 AND CD15s IN METASTASIS FROM LUNG TO THE BRAIN
Authors: Samah Jassam, Zaynah Maherally, Keyoumars Ashkan, Geoffrey Pilkington, Helen Fillmore
Journal: Neuro-Oncology (2016)

Metastatic non-small cell lung cancer represents one of the most common brain metastasis in adults. Interaction between circulating cancer cells and brain endothelial cells play a key role in brain metastasis, but their underlining molecular mechanisms are still not fully understood. The CD15 and CD15s epitopes function as cell adhesion molecules and are correlated with metastasis in non-CNS cancers. The role of CD15 and CD15s in lung cancer cell adhesion and trans-brain-endothelial migration was investigated by perturbing the expression of the fucosyltransferases responsible for the synthesis of these epitopes. Genes encoding fucosyltransferase4 (FUT4) responsible for CD15 and fucosyltransferase7 (FUT7) for CD15s were genetically manipulated in four human cancer cell lines: metastatic lung to brain cancer (SEBTA-001), metastatic lung to lymph node (NCI-H1299), primary lung carcinoma (COR-L105) and glioblastoma (UP-007). Adhesion and trans-endothelial migration ability as measured by voltmeter (EVOM™), electric cell-substrate impedance sensing (ECIS) system and CellZscope® were evaluated. Our results demonstrate that both FUT4 and FUT7 induced expression resulted in an increase in adhesion in all cancer cells (p<0.01) while, FUT4 and FUT7 silencing led to a decrease in adhesion compared to wild type controls (p<0.01). Cell lines forced to overexpress FUT4 or 7 and then added onto an endothelial monolayer caused an immediate decrease in trans-endothelial electrical resistance (TEER) compared to knockdown and control cells (p<0.01). Knockdown of either FUT4 or 7 in metastatic cell lines known to transmigrate lost the ability to generate a decrease in TEER compared to control cells (p<0.01). In summary, this study highlights the importance of CD15 and CD15s specifically in adhesion and potentially the transendothelial migration of NSCLC cells to the brain. Targeting these carbohydrate epitopes or the enzymes responsible for their presence might contribute to reducing brain metastasis.
A phase I open-label study of Ad-RTS-hIL-12, an adenoviral vector engineered to express hIL-12 under the control of an oral activator ligand, in subjects with unresectable stage III/IV melanoma.
Authors: Gerald P. Linette, Omid Hamid, Eric D. Whitman, John J. Nemunaitis, Jason Chesney, Sanjiv S. Agarwala, Alexander Starodub, John A Barrett, Andrew Marsh, Lori A. Martell, Angela Cho, Thomas D. Reed, Hagop Youssoufian, Andrea Vergara-Silva
Journal: Journal of Clinical Oncology (2013)

3022 Background: IL-12 is a pleiotropic cytokine with known antitumor activity; however, clinical use was limited by toxicity when delivered systemically. Ad-RTS-hIL-12 is an adenoviral vector engineered for controlled expression of IL-12 with the RheoSwitch Therapeutic System (RTS) and an oral activator, INXN-1001. Methods: In a phase I, 3+3 dose escalation study, subjects with unresectable stage III/IV melanoma were administered 1e12 viral particles (Ad-RTS-hIL-12) intratumorally on the first day of up to six 21-day cycles, and INXN-1001 (5, 20, 100, and 160 mg) orally on days 1-7 of each cycle. Results: Dose escalation is complete with 14 subjects treated. Median prior therapeutic agents was 3 (range 1-4). Common related adverse events included chills (11, 78.6%), pyrexia (11, 78.6%), fatigue (10, 71.4%), and nausea (10, 71.4%). With a biologically effective dose of 160 mg, MTD for INXN-1001 was not reached. One death unrelated to study drug was secondary to septicemia. Clinical activity was observed in 5 of 7 subjects treated at doses of INXN-1001 ≥100 mg, but not at &lt;100 mg, and included prominent inflammatory responses in injected and non-injected lesions, decreases in size of injected and non-injected lesions, and reduction in tumor-associated pain. One subject at the 160-mg dose had stable disease for 20 weeks. Clinical activity in dose cohorts ≥100 mg coincided with a 4-fold median increase from baseline in peak serum levels of IL-12 and IFN-γ compared with lower dose cohorts. Flow cytometric analyses of PBMCs revealed 7-fold (≥100 mg dose cohorts) median increases from baseline in peak levels of absolute numbers of CD3+ and CD8+ T cells. ELISPOT and T-cell proliferation assays for antigen-specific responses are ongoing. Conclusions: Intratumoral delivery of IL-12 via an adenoviral vector with RheoSwitch enabled finely-controlled expression of IL-12 levels by an oral ligand. Ad-RTS-hIL-12 plus INXN-1001 (160 mg) was well tolerated and induced biological and clinical activity in subjects with advanced melanoma. Phase II studies are ongoing at the biologically effective dose. Clinical trial information: NCT01397708.
Perioperative triplet chemotherapy plus bevacizumab (bev) in patients with borderline resectable colorectal cancer liver metastases (CLM): Preliminary safety and activity
Authors: A. Mennitto, C. Cotsoglou, M. Caporale, M. Scotti, R. Berenato, J. Coppa, M. Di Bartolomeo, M. Milione, I. Bossi, F. de Braud, V. Mazzaferro, P. Filippo
Journal: Annals of Oncology (2016)
TMOD-38. DEVELOPMENT OF AN IN VITRO GLIOBLASTOMA CANCER STEM CELL BANK
Authors: Brent Reynolds, Vinata Vedam-mai, Loic Deleyrolle
Journal: Neuro-Oncology (2016)

The Preston A. Wells Jr. Glioma Cell Line Bank began collecting tissue from UF glioma neurosurgical operations in 2014 and has established an organized repository of immortalized glioma cell lines that have been collected and maintained in a manner useful for a wide range of studies. Copies of patient’s consent to donate their tissue is obtained and clinical data from each case is logged into a secured computer database. Tissue is placed in culture as soon as it is received and the line is founded using the serum-free neurosphere method. Once a line is established, it is expanded and 100 vials are cryopreserved and separated into a “working” or “master” cell source. Each cell line is implanted orthotopically into immunocompromised hosts to confirm in vivo tumorgenicity. Expression profiling is used to subtype the line and to provide a database to identify common or unique gene expression characteristics for each patient derived line. Information on the lines, in vitro growth characteristics, stem cell frequency, in vivo tumor formation and the expression profile will be made publically available via UF web servers. The cell lines are hosted at the Florida Center for Brain Tumor Research [FCBTR] and scientists can submit a request form to the Manager to obtain cryopreserved cell lines. This form requires an explanation of the tissue requested (type, number of samples, justification), description of the study, approval and authorization. After the request has been approved, the cell line] is sent to the recipient. Monthly and annual reports are generated, including the numbers of cases collected, pathologic diagnoses, quantity of tissue collected and viability of the line if successfully banked. Development of the Bank is supported by competitive, peer-reviewed federal grant and is maintained by user fees, Preston A. Wells, Jr. Center for Brain Tumor Therapy and the FCBTR.
Genomic loss of heterozygosity (LOH) and survival in patients (pts) treated with epirubicin, oxaliplatin, capecitabine (EOC) ± panitumumab (P) in the REAL3 trial
Authors: C. Cafferkey, E. Smyth, A. Loehr, T. Harding, M. Raponi, A. Okines, T. Waddell, I. Chau, D. Cunningham
Journal: Annals of Oncology (2016)
Nine-Year Longitudinal Psychosocial and Mental Outcomes of a Stress Management Intervention at Work Using Psychotherapeutic Principles
Authors: Jian Li, Natalie Riedel, Amira Barrech, Raphael M. Herr, Birgit Aust, Kathrin Mörtl, Johannes Siegrist, Harald Gündel, Peter Angerer
Journal: Psychotherapy and Psychosomatics (2017)
Incidence and Prognostic Impact of Gene Mutations in Older Patients with AML Treated in the ALFA-9801 Study.
Authors: Aline Renneville, Sylvie Castaigne, Sylvie Chevret, Laura Llopis, Nathalie Philippe, Olivier Nibourel, Sandrine Hayette, Jean-Michel Cayuela, Dina Naguib, Nathalie Gachard, Dominique Bories, Christian Bastard, Fatiha Merabet, Cécile Pautas, Christine Terré, Xavier Thomas, Hervé Dombret, Claude Preudhomme
Journal: Blood (2008)
The MyD88 Adapter-Like (Mal) Protein Variant Leu 180, a Candidate Polymorphism for Protection Against Graft Versus Host Disease.
Authors: Udo Holtick, Peter G. Middleton, Jane L. Harrold, Ernst Holler, Eliane Gluckman, Ilona Hromadnikova, Anne M. Dickinson, Matthew P. Collin
Journal: Blood (2006)
Transmission of Zika Virus — Haiti, October 12, 2015–September 10, 2016
Authors: Ito Journel, Lesly L. Andrécy, Dudley Metellus, Jean S. Pierre, Rose Murka Faublas, Stanley Juin, Amber M. Dismer, David L. Fitter, Daniel Neptune, Marie José Laraque, Salomon Corvil, Manise Pierre, Josiane Buteau, Donald Lafontant, Roopal Patel, Jean Frantz Lemoine, David W. Lowrance, Macarthur Charles, Jacques Boncy, Paul Adrien
Journal: MMWR Morbidity and Mortality Weekly Report (2017)

Zika virus disease is caused by infection with a flavivirus with broad geographic distribution and is most frequently transmitted by the bite of an infected mosquito. The disease was first identified in the World Health Organization's Region of the Americas in 2015 and was followed by a surge in reported cases of congenital microcephaly in Brazil; Zika virus disease rapidly spread to the rest of the region and the Caribbean (1), including Haiti. Infection with the virus is associated with adverse fetal outcomes (1) and rare neurologic complications in adults. The magnitude of public health issues associated with Zika virus led the World Health Organization to declare the Zika virus outbreak a Public Health Emergency of International Concern on February 1, 2016 (2). Because many persons with mild Zika virus disease are asymptomatic and might not seek care, it is difficult to estimate the actual incidence of Zika virus infection. During October 12, 2015-September 10, 2016, the Haitian Ministry of Public Health and Population (Ministère de la Santé Publique et de la Population [MSPP]) detected 3,036 suspected cases of Zika virus infection in the general population, 22 suspected cases of Zika virus disease among pregnant women, 13 suspected cases of Guillain-Barré syndrome (GBS), and 29 suspected cases of Zika-associated congenital microcephaly. Nineteen (0.6%) patients with suspected Zika virus disease, residing in Ouest (10 patients), Artibonite (six), and Centre (three) administrative departments,* have been confirmed by laboratory testing, including two among pregnant women and 17 in the general population. Ongoing laboratory-enhanced surveillance to monitor Zika virus disease in Haiti is important to understanding the outbreak and ensuring effective response activities.
Participants in women’s health intervention trials show improved health outcomes
Authors: Ingrid Torjesen
Journal: BMJ (2017)

Women who participate in obstetric and gynaecological clinical trials experience better health outcomes than those not involved in trials, shows a study published in BJOG: An International Journal of Obstetrics and Gynaecology .1

The review of 21 studies, which included 20 160 women who experienced 4759 outcome events, found that women who participated in trials had 25% better odds of improved health outcomes than non-participants (odds ratio 0.75 (95% confidence interval 0.64 to 0.87); I2=64.3%). …
Cardiovascular Involvement in Thalassemia Major Patients: WEB-THAL® Data Analysis (A Web-Based Multicentric Database).
Authors: Giorgio Derchi, Francesco Formisano, Martina Lamagna, Renzo Galanello, Patrizio Bina, Maria Domenica Cappellini, Maria Rosaria Fasulo, Antonio Piga, Guido Donato, Gianni Quarta, Angela Melpignano, Carla Tazzer, Gian Luca Forni
Journal: Blood (2007)
Extramedullary Relapse of Acute Adult Leukemia Following Allogeneic Stem Cell Transplantation:10 Cases Analysis.
Authors: Jimin Shi, Yi Luo, Yamin Tan, Xiaoli Zhu, Jingsong He, Weiyan Zheng, Wanzhuo Xie, Li Li, Xiujin Ye, Jie Zhang, Zhen Cai, Maofang Lin, He Huang
Journal: Blood (2010)